Clinical trials: Wet Macular Degeneration
Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration
Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting
This study will describe the long-term safety and effectiveness, treatment patterns,and patient reported quality of life associated with ranibizumab treatment in routine clinical practice for all approved indication included in…
- Conditions
- Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- LUMINOUS (NCT01318941)
- Testing
- Ranibizumab
- Where
- 463 sites in Argentina, Australia and 41 more
- Volunteers
- 30,490 people
- Sponsor
- Novartis Pharmaceuticals
Dry Age-related Macular Degeneration
A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
To evaluate the safety and exploratory efficacy of 1.0mg of Luminate® in patients with Intermediate Non-Exudative Macular Degeneration
- Trial name
- NCT03626636
- Testing
- Risuteganib
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Allegro Ophthalmics, LLC
Wet Macular Degeneration
Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
This is a prospective randomised study comparing two intravitreal antiVEGF drugs - brolucizumab and aflibercept - in the treatment of retinal angiomatous proliferation (RAP).
- Trial name
- BEY-RAP (NCT04698850)
- Testing
- Aflibercept 40 MG/ML [Eylea], Brolucizumab-Dbll 120 MG/ML [Beovu], Ranibizumab 6 MG/ML [Lucentis]
- Where
- Czechia
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Neovascular Age-related Macular Degeneration
Gene Therapy for Wet AMD
FT-003 is a gene therapy product developed for the treatment of neovascular age-related macular degeneration (nAMD). Neovascular AMD is the main cause of blindness among elderly individuals.
- Trial name
- NCT05611424
- Testing
- FT-003
- Volunteers
- 18 people
- Sponsor
- Frontera Therapeutics
Neovascular Age-related Macular Degeneration
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.
- Trial name
- SALT (NCT01958918)
- Testing
- Ranibizumab, Aflibercept
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 712 people
- Sponsor
- Novartis Pharmaceuticals
Wet Macular Degeneration
Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration
The objective of this pilot study is to evaluate the efficacy of intensive fixed monthly dosing of intravitreal Lucentis® (Ranibizumab) for the treatment of SRF and PED in neovascular AMD which is persistent to anti-VEGF…
- Trial name
- NCT02944227
- Testing
- Lucentis
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Advanced Age-related Macular Degeneration
Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration
This study will assess the safety, tolerability, and serum pharmacokinetics of intravitreal LFG316 in patients with advanced age-related macular degeneration.
- Trial name
- NCT01255462
- Testing
- LFG316
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration
Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF
This study is a double-masked, randomized, placebo-controlled study of the safety and preliminary efficacy of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either ranibizumab or bevacizumab.
- Trial name
- NCT00607750
- Testing
- ATG003 (mecamylamine)
- Volunteers
- 60 people
- Sponsor
- CoMentis
Wet Age-related Macular Degeneration (wAMD), Wet Age-related Macular Degeneration
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).
- Trial name
- NCT06888492
- Testing
- EXG202
- Where
- 2 sites in China
- Volunteers
- 8 people
- Sponsor
- Guangzhou Jiayin Biotech Ltd
Macular Degeneration
Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD
The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.
- Trial name
- NCT00065728
- Testing
- Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Alcon Research
Age Related Macular Degeneration
A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.
- Trial name
- NCT04740671
- Testing
- HLX04-O, ranibizumab
- Where
- 126 sites in United States, Australia and 13 more
- Volunteers
- 410 people
- Sponsor
- Shanghai Henlius Biotech
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (nAMD) also referred to as Wet AMD.
- Conditions
- Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration
- Trial name
- NCT04832724
- Testing
- RGX-314
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- AbbVie
AMD
Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD
This is an observational study in which patients affected by dry or wet AMD will be enrolled, after signing the Informed Consent, according to eligibility criteria.
- Trial name
- NCT04177069
- Testing
- Visucomplex Plus
- Where
- 4 sites in Italy
- Volunteers
- 160 people
- Sponsor
- VISUfarma SpA
Age Related Macular Degeneration
Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
this study will compare the efficacy and safety of HLX04-O administered by IVT with ranibizumab in patients with active CNV secondary to AMD.
- Trial name
- NCT05003245
- Testing
- HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis
- Where
- 41 sites in China
- Volunteers
- 407 people
- Sponsor
- Shanghai Henlius Biotech
Neovascular Age Related Macular Degeneration
A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)
Study Design This is a Single-center, Phase I/II placebo-controlled study to assess the safety and efficacy of PRL3-zumab in patients with Neovascular Age-related Macular Degeneration (nAMD).
- Trial name
- NCT07547228
- Testing
- PRL3-ZUMAB, Normal Saline (0.9% Sodium Chloride)
- Where
- Singapore
- Volunteers
- 15 people
- Sponsor
- Intra-IMMUSG Pte Ltd
Neovascular Age-related Macular Degeneration
Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration
Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of suprachoroidally administered CLS-AX 1.0 mg with a flexible dosing regimen in…
- Trial name
- ODYSSEY (NCT05891548)
- Testing
- CLS-AX, Aflibercept
- Where
- 32 sites in United States
- Volunteers
- 60 people
- Sponsor
- Clearside Biomedical, Inc.
Macular Diseases
Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL
In just a few years, intravitreal injections have become a standard method of administration for certain retinal deseases (age-related macular degeneration [AMD], diabetic edematous maculopathy or retinal vein occlusion [RVO]).
- Trial name
- AFLIPIO (NCT06893965)
- Testing
- Intra ocular pressure Measure
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Macular Degeneration, Stargardt's Macular Dystrophy
Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases
The purpose of this study was to determine the safety and therapeutic effect of sub-retinal transplantation of human embryo stem cell derived retinal pigment epitheliums (hESC-RPE) in patients with macular degeneration diseases…
- Trial name
- NCT02749734
- Testing
- Subretinal transplantation
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Southwest Hospital, China
Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD)
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
The purpose of this research study is to observe the patient's clinical care and how EYLEA® HD is used as a treatment in real-world settings.
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment
- Trial name
- SPECTRUM-US (NCT06398080)
- Testing
- aflibercept 8 mg
- Sponsor
- Regeneron Pharmaceuticals
Age Related Macular Degeneration
Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections
SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in patients with wet age related macular degeneration who have incomplete response with routineranibizumab treatment.
- Trial name
- SHIFT-2 (NCT02002377)
- Testing
- Aflibercept
- Where
- 9 sites in Canada
- Volunteers
- 23 people
- Sponsor
- Unity Health Toronto